BLB-201 is under clinical development by Blue Lake Biotechnology and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase II drugs for Respiratory Syncytial Virus (RSV) Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BLB-201 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BLB-201 overview
BLB-201 is under development for the prevention of respiratory syncytial virus (RSV) infections. The therapeutic candidate is a Parainfluenza virus 5 (PIV5 and CPI strain) amplifying virus-like particles expressing respiratory syncytial virus (RSV) antigens. It is administered through intranasal route. The vaccine candidate is developed based on parainfluenza virus 5 (PIV5) platform.
Blue Lake Biotechnology overview
Blue Lake Biotechnology (Blue Lake Biotech) is a vaccine company focusing on developing human vaccines using novel technology. The company is headquartered in Athens, Georgia, the US.
For a complete picture of BLB-201’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
